semaglutide approved by fda The a pill version of the GLP-1 receptor agonist (Wegovy), making it the first oral GLP-1 agent indicated for weight loss, Novo Nordisk announced on Monday. The once-daily 25 FDA issues warning about some

Postprandial hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: an update

Single-source raw material dependency (Protein A resin, specific cell culture media components) is the primary supply chain systemic risk for biosimilar manufacturers and should be addressed in risk management planning with dual-sourcing qualification

some people experience mild side effects such as nausea or stomach discomfort when they first start

These medications work very similarly to GLP-1 medications like Ozempic, except that they also mimic a gut hormone called glucose-dependent insulinotropic polypeptide (GIP)

As a GLP-1 receptor agonist, it mimics the hormone glucagon-like peptide-1, which your body naturally releases after eating